504 related articles for article (PubMed ID: 31411998)
1. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.
Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB
Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998
[TBL] [Abstract][Full Text] [Related]
2. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
Macleod LC; Yabes JG; Yu M; Fam MM; Hale NE; Turner RM; Lopa SH; Gingrich JR; Borza T; Skolarus TA; Davies BJ; Jacobs BL
Urol Oncol; 2019 Jul; 37(7):462-469. PubMed ID: 31053530
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
5. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
[TBL] [Abstract][Full Text] [Related]
6. Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015.
Nyame YA; Holt SK; Diamontopoulos LN; Winters BR; Psutka SP; Dash A; Schade GR; Lin DW; Yu EY; Grivas P; Gore JL; Wright JL
Urology; 2021 Mar; 149():154-160. PubMed ID: 33373709
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
8. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
[TBL] [Abstract][Full Text] [Related]
9. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.
Peyton CC; Tang D; Reich RR; Azizi M; Chipollini J; Pow-Sang JM; Manley B; Spiess PE; Poch MA; Sexton WJ; Fishman M; Zhang J; Gilbert SM
JAMA Oncol; 2018 Nov; 4(11):1535-1542. PubMed ID: 30178038
[TBL] [Abstract][Full Text] [Related]
10. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
Lane G; Risk M; Fan Y; Krishna S; Konety B
BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
[TBL] [Abstract][Full Text] [Related]
11. Use of radical cystectomy for patients with invasive bladder cancer.
Gore JL; Litwin MS; Lai J; Yano EM; Madison R; Setodji C; Adams JL; Saigal CS;
J Natl Cancer Inst; 2010 Jun; 102(11):802-11. PubMed ID: 20400716
[TBL] [Abstract][Full Text] [Related]
12. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015.
Fisher MD; Shenolikar R; Miller PJ; Fenton M; Walker MS
Clin Genitourin Cancer; 2018 Dec; 16(6):e1171-e1179. PubMed ID: 30206026
[TBL] [Abstract][Full Text] [Related]
14. Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?
Grossman HB; Bellmunt J; Black PC
Eur Urol Oncol; 2019 Sep; 2(5):597-602. PubMed ID: 31279815
[TBL] [Abstract][Full Text] [Related]
15. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy.
Mazzone E; Nazzani S; Knipper S; Tian Z; Preisser F; Gallina A; Soulières D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Wisnivesky J; Karakiewicz PI
Eur J Surg Oncol; 2019 Jul; 45(7):1253-1259. PubMed ID: 30755341
[TBL] [Abstract][Full Text] [Related]
16. Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea.
Kim SH; Seo HK; Shin HC; Chang SJ; Yun S; Joo J; Ku JH; Kim HS; Jeon HG; Jeong BC; Jeong IG; Kang SH; Hong B;
J Korean Med Sci; 2015 Aug; 30(8):1150-6. PubMed ID: 26240494
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.
Fischer-Valuck BW; Rao YJ; Rudra S; Przybysz D; Germino E; Samson P; Baumann BC; Gay H; Michalski J
J Urol; 2018 Feb; 199(2):416-423. PubMed ID: 28842247
[TBL] [Abstract][Full Text] [Related]
18. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
19. Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion.
Rosiello G; Knipper S; Palumbo C; Pecoraro A; Luzzago S; Deuker M; Tian Z; Gandaglia G; Gallina A; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2020 Feb; 18(1):35-44.e1. PubMed ID: 31711842
[TBL] [Abstract][Full Text] [Related]
20. Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice.
Booth CM; Siemens DR; Peng Y; Tannock IF; Mackillop WJ
Ann Oncol; 2014 Sep; 25(9):1783-1788. PubMed ID: 24915872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
